| Year |
Citation |
Score |
| 2023 |
Ciocănea-Teodorescu I, Goetghebeur E, Waernbaum I, Schön S, Gabriel EE. Causal inference in survival analysis under deterministic missingness of confounders in register data. Statistics in Medicine. PMID 36890728 DOI: 10.1002/sim.9706 |
0.331 |
|
| 2020 |
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, Bruycker AD, Lambert B, Delrue L, Bultijnck R, Goetghebeur E, Villeirs G, Man KD, Ameye F, Billiet I, Joniau S, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial. Journal of Clinical Oncology. 38: 10-10. DOI: 10.1200/Jco.2020.38.6_Suppl.10 |
0.336 |
|
| 2020 |
Bruycker AD, Spiessens A, Dirix P, Koutsouvelis N, Semac I, Liefhooghe N, Gomez-Iturriaga A, Everaerts W, Otte F, Papachristofilou A, Scorsetti M, Shelan M, Siva S, Ameye F, Guckenberger M, ... ... Goetghebeur E, et al. PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): a study protocol for a randomized controlled phase II trial. Bmc Cancer. 20: 406. DOI: 10.1186/S12885-020-06911-4 |
0.388 |
|
| 2019 |
Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, De Maeseneer D, Reynders D, Goetghebeur E, Van Dorpe J, Verbeke S, Annala M, Brochez L, Van der Eecken K, Wyatt AW, et al. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. European Urology. 75: 707-711. PMID 30665814 DOI: 10.1016/J.Eururo.2019.01.009 |
0.376 |
|
| 2019 |
Vandekerkhove G, Sundahl N, Decaestecker K, Meireson A, Visschere PD, Fonteyne V, Maeseneer DJD, Reynders D, Goetghebeur E, Dorpe JV, Verbeke S, Annala M, Brochez L, Eecken KVd, Wyatt AW, et al. Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results. Journal of Clinical Oncology. 37: 422-422. DOI: 10.1200/Jco.2019.37.7_Suppl.422 |
0.387 |
|
| 2019 |
Ost P, Sundahl N, Vandekerkhove G, Decaestecker K, Meireson A, Visschere PD, Fonteyne V, Maeseneer DD, Reynders D, Goetghebeur E, Dorpe JV, Verbeke S, Annala M, Brochez L, Eecken KVd, et al. Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)31525-8 |
0.363 |
|
| 2018 |
Sundahl N, De Wolf K, Kruse V, Meireson A, Reynders D, Goetghebeur E, Van Gele M, Speeckaert R, Hennart B, Brochez L, Ost P. Phase 1 Dose Escalation Trial of Ipilimumab and Stereotactic Body Radiation Therapy in Metastatic Melanoma. International Journal of Radiation Oncology, Biology, Physics. 100: 906-915. PMID 29485070 DOI: 10.1016/J.Ijrobp.2017.11.029 |
0.312 |
|
| 2018 |
Sundahl N, Rottey S, Decaestecker K, visschere PD, maeseneer DD, Reynders D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, Brochez L, Ost P. OC-0682: Phase 1 trial of pembrolizumab with SBRT in metastatic urothelial carcinoma Radiotherapy and Oncology. 127. DOI: 10.1016/S0167-8140(18)30992-7 |
0.314 |
|
| 2017 |
Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, Lambert B, Delrue L, Bultijnck R, Claeys T, Goetghebeur E, Villeirs G, De Man K, Ameye F, Billiet I, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017754853. PMID 29240541 DOI: 10.1200/Jco.2017.75.4853 |
0.356 |
|
| 2017 |
Sundahl N, De Wolf K, Rottey S, Decaestecker K, De Maeseneer D, Meireson A, Goetghebeur E, Fonteyne V, Verbeke S, De Visschere P, Reynders D, Van Gele M, Brochez L, Ost P. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Journal of Translational Medicine. 15: 150. PMID 28662677 DOI: 10.1186/S12967-017-1251-3 |
0.316 |
|
| 2015 |
Berwouts D, De Wolf K, Lambert B, Bultijnck R, De Neve W, De Lobel L, Jans L, Goetghebeur E, Speleers B, Olteanu LA, Madani I, Goethals I, Ost P. Biological 18[F]-FDG-PET image-guided dose painting by numbers for painful uncomplicated bone metastases: A 3-arm randomized phase II trial. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. 115: 272-8. PMID 25981049 DOI: 10.1016/J.Radonc.2015.04.022 |
0.347 |
|
| 2014 |
Varewyck M, Goetghebeur E, Eriksson M, Vansteelandt S. On shrinkage and model extrapolation in the evaluation of clinical center performance. Biostatistics (Oxford, England). 15: 651-64. PMID 24812420 DOI: 10.1093/Biostatistics/Kxu019 |
0.353 |
|
| 2013 |
Buyze J, Goetghebeur E. Evaluating dynamic treatment strategies: does it have to be more costly? Pharmaceutical Statistics. 12: 35-42. PMID 23208788 DOI: 10.1002/Pst.1546 |
0.424 |
|
| 2013 |
Buyze J, Goetghebeur E. Crossover studies with survival outcomes. Statistical Methods in Medical Research. 22: 612-29. PMID 21715438 DOI: 10.1177/0962280211402258 |
0.374 |
|
| 2012 |
Lievens A, Van Aelst S, Van den Bulcke M, Goetghebeur E. Simulation of between repeat variability in real time PCR reactions. Plos One. 7: e47112. PMID 23189123 DOI: 10.1371/Journal.Pone.0047112 |
0.31 |
|
| 2012 |
Van Rompaye B, Jaffar S, Goetghebeur E. Estimation with Cox models: Cause-specific survival analysis with misclassified cause of failure Epidemiology. 23: 194-202. PMID 22317803 DOI: 10.1097/Ede.0B013E3182454Cad |
0.408 |
|
| 2012 |
Möberg K, De Nobele S, Devos D, Goetghebeur E, Segers P, Trachet B, Vervaet C, Renard M, Coucke P, Loeys B, De Paepe A, De Backer J. The Ghent Marfan Trial--a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers. International Journal of Cardiology. 157: 354-8. PMID 21239069 DOI: 10.1016/J.Ijcard.2010.12.070 |
0.374 |
|
| 2011 |
Fischer K, Goetghebeur E, Vrijens B, White IR. A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments. Biostatistics (Oxford, England). 12: 247-57. PMID 20805286 DOI: 10.1093/Biostatistics/Kxq053 |
0.476 |
|
| 2011 |
Quataert P, Verschelde P, Breine J, Verbeke G, Goetghebeur E, Ollevier F. A diagnostic modelling framework to construct indices of biotic integrity: A case study of fish in the Zeeschelde estuary (Belgium) Estuarine Coastal and Shelf Science. 94: 222-233. DOI: 10.1016/J.Ecss.2011.06.014 |
0.301 |
|
| 2010 |
Goetghebeur E. Commentary: To cause or not to cause confusion vs transparency with Mendelian Randomization. International Journal of Epidemiology. 39: 918-20. PMID 20483834 DOI: 10.1093/Ije/Dyq100 |
0.305 |
|
| 2010 |
Van Rompaye B, Goetghebeur E, Jaffar S. Design and testing for clinical trials faced with misclassified causes of death Biostatistics. 11: 546-558. PMID 20212319 DOI: 10.1093/Biostatistics/Kxq011 |
0.366 |
|
| 2010 |
Buyze J, Van Rompaye B, Goetghebeur E. Designing a sequentially randomized study with adherence enhancing interventions for diabetes patients. Statistics in Medicine. 29: 1114-26. PMID 20101597 DOI: 10.1002/Sim.3856 |
0.349 |
|
| 2010 |
Tolley EE, Harrison PF, Goetghebeur E, Morrow K, Pool R, Taylor D, Tillman SN, van der Straten A. Adherence and its measurement in phase 2/3 microbicide trials. Aids and Behavior. 14: 1124-36. PMID 19924525 DOI: 10.1007/S10461-009-9635-X |
0.391 |
|
| 2010 |
Babanezhad M, Vansteelandt S, Goetghebeur E. Comparison of causal effect estimators under exposure misclassification Journal of Statistical Planning and Inference. 140: 1306-1319. DOI: 10.1016/J.Jspi.2009.11.015 |
0.375 |
|
| 2007 |
Tian L, Cai T, Goetghebeur E, Wei LJ. Model evaluation based on the sampling distribution of estimated absolute prediction error Biometrika. 94: 297-311. DOI: 10.1093/Biomet/Asm036 |
0.317 |
|
| 2006 |
Loeys T, Goetghebeur E, Vandebosch A. Causal proportional hazards models and time-constant exposure in randomized clinical trials. Lifetime Data Analysis. 11: 435-49. PMID 16328570 DOI: 10.1007/S10985-005-5233-Z |
0.648 |
|
| 2005 |
Goetghebeur E, Stijn V. Structural mean models for compliance analysis in randomized clinical trials and the impact of errors on measures of exposure. Statistical Methods in Medical Research. 14: 397-415. PMID 16178139 DOI: 10.1191/0962280205Sm407Oa |
0.425 |
|
| 2005 |
Dunn G, Goetghebeur E. Analysing compliance in clinical trials. Statistical Methods in Medical Research. 14: 325-6. PMID 16178135 DOI: 10.1191/0962280205Sm402Ed |
0.378 |
|
| 2005 |
Vandebosch A, Goetghebeur E, Van Damme L. Structural accelerated failure time models for the effects of observed exposures on repeated events in a clinical trial. Statistics in Medicine. 24: 1029-46. PMID 15558726 DOI: 10.1002/sim.1988 |
0.377 |
|
| 2005 |
Vansteelandt S, Goetghebeur E. Sense and sensitivity when correcting for observed exposures in randomized clinical trials. Statistics in Medicine. 24: 191-210. PMID 15515152 DOI: 10.1002/Sim.1829 |
0.489 |
|
| 2004 |
Vrijens B, Goetghebeur E. Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies. Statistics in Medicine. 23: 531-44. PMID 14755387 DOI: 10.1002/Sim.1619 |
0.312 |
|
| 2004 |
Fischer K, Goetghebeur E. Structural Mean Effects of Noncompliance: Estimating Interaction With Baseline Prognosis and Selection Effects Journal of the American Statistical Association. 99: 918-928. DOI: 10.1198/016214504000001268 |
0.418 |
|
| 2003 |
Loeys T, Goetghebeur E. A Causal Proportional Hazards Estimator for the Effect of Treatment Actually Received in a Randomized Trial with All-or-Nothing Compliance Biometrics. 59: 100-105. DOI: 10.1111/1541-0420.00012 |
0.658 |
|
| 2003 |
Vansteelandt S, Goetghebeur E. Causal inference with generalized structural mean models Journal of the Royal Statistical Society Series B-Statistical Methodology. 65: 817-835. DOI: 10.1046/J.1369-7412.2003.00417.X |
0.431 |
|
| 2002 |
Goetghebeur E, Vansteelandt S. Discussion of 'Clustered encouragement designs with individual noncompliance: Bayesian inference with randomization, and application to advance directive forms' by Frangakis, Rubin and Zhou. Biostatistics (Oxford, England). 3: 169-71; discussion 1. PMID 12933611 DOI: 10.1093/Biostatistics/3.2.169 |
0.469 |
|
| 2002 |
Goetghebeur E, Loeys T. Beyond intention to treat. Epidemiologic Reviews. 24: 85-90. PMID 12119861 DOI: 10.1093/Epirev/24.1.85 |
0.64 |
|
| 2002 |
Loeys T, Goetghebeur E. Baseline information in structural failure time estimators for the effect of observed treatment compliance. Statistics in Medicine. 21: 1173-88. PMID 12111873 DOI: 10.1002/Sim.1087 |
0.655 |
|
| 2001 |
Loeys T, Vansteelandt S, Goetghebeur E. Accounting for correlation and compliance in cluster randomized trials. Statistics in Medicine. 20: 3753-3767. PMID 11782031 DOI: 10.1002/Sim.1169 |
0.62 |
|
| 2001 |
Vansteelandt S, Goetghebeur E. Analyzing the sensitivity of generalized linear models to incomplete outcomes via the IDE algorithm Journal of Computational and Graphical Statistics. 10: 656-672. DOI: 10.1198/106186001317243386 |
0.336 |
|
| 2000 |
Goetghebeur E, Ryan L. Semiparametric Regression Analysis of Interval-Censored Data Biometrics. 56: 1139-1144. PMID 11129472 DOI: 10.1111/J.0006-341X.2000.01139.X |
0.388 |
|
| 2000 |
Vansteelandt S, Goetghebeur E, Verstraeten T. Regression models for disease prevalence with diagnostic tests on pools of serum samples. Biometrics. 56: 1126-1133. PMID 11129470 DOI: 10.1111/J.0006-341X.2000.01126.X |
0.331 |
|
| 2000 |
Goetghebeur E, Liinev J, Boelaert M, Stuyft PVd. Diagnostic test analyses in search of their gold standard: latent class analyses with random effects Statistical Methods in Medical Research. 9: 231-248. PMID 11084706 DOI: 10.1177/096228020000900304 |
0.341 |
|
| 2000 |
Korhonen P, Loeys T, Goetghebeur E, Palmgren J. Vitamin A and infant mortality: beyond intention-to-treat in a randomized trial. Lifetime Data Analysis. 6: 107-21. PMID 10851837 DOI: 10.1023/A:1009670105608 |
0.651 |
|
| 1999 |
Boelaert M, Aoun K, Liinev J, Goetghebeur E, Stuyft PVD. The potential of latent class analysis in diagnostic test validation for canine Leishmania infantum infection. Epidemiology and Infection. 123: 499-506. PMID 10694163 DOI: 10.1017/S0950268899003040 |
0.304 |
|
| 1999 |
Vrijens B, Goetghebeur E. The impact of compliance in pharmacokinetic studies Statistical Methods in Medical Research. 8: 247-262. PMID 10636337 DOI: 10.1177/096228029900800305 |
0.361 |
|
| 1999 |
Boelaert M, el Safi S, Goetghebeur E, Gomes-Pereira S, Le Ray D, Van der Stuyft P. Latent class analysis permits unbiased estimates of the validity of DAT for the diagnosis of visceral leishmaniasis. Tropical Medicine & International Health : Tm & Ih. 4: 395-401. PMID 10402977 DOI: 10.1046/J.1365-3156.1999.00421.X |
0.396 |
|
| 1998 |
Goetghebeur E, Molenberghs G, Katz J. Estimating the causal effect of compliance on binary outcome in randomized controlled trials Statistics in Medicine. 17: 341-355. PMID 9493258 DOI: 10.1002/(Sici)1097-0258(19980215)17:3<341::Aid-Sim766>3.0.Co;2-X |
0.467 |
|
| 1998 |
White IR, Goetghebeur EJ. Clinical trials comparing two treatment policies: which aspects of the treatment policies make a difference? Statistics in Medicine. 17: 319-39. PMID 9493257 DOI: 10.1002/(SICI)1097-0258(19980215)17:3<319::AID-SIM765>3.0.CO;2-F |
0.338 |
|
| 1998 |
Goetghebeur E. Analyzing non-compliance in clinical trials: preface Statistics in Medicine. 17: 247-247. DOI: 10.1002/(Sici)1097-0258(19980215)17:3<247::Aid-Sim840>3.0.Co;2-Z |
0.374 |
|
| 1997 |
Fischer-Lapp K, Goetghebeur E. Practical Properties of Some Structural Mean Analyses of the Effect of Compliance in Randomized Trials Controlled Clinical Trials. 20: 531-546. PMID 10588294 DOI: 10.1016/S0197-2456(99)00027-6 |
0.485 |
|
| 1997 |
Vrijens B, Goetghebeur E. Comparing compliance patterns between randomized treatments. Controlled Clinical Trials. 18: 187-203. PMID 9204220 DOI: 10.1016/S0197-2456(96)00235-8 |
0.345 |
|
| 1997 |
Goetghebeur E, Lapp K. The Effect of Treatment Compliance in a Placebo-controlled Trial: Regression with Unpaired Data Journal of the Royal Statistical Society: Series C (Applied Statistics). 46: 351-364. DOI: 10.1111/1467-9876.00074 |
0.303 |
|
| 1997 |
Molenberghs G, Goetghebeur E. Simple fitting algorithms for incomplete categorical data Journal of the Royal Statistical Society. Series B: Statistical Methodology. 59: 401-414. DOI: 10.1111/1467-9868.00075 |
0.332 |
|
| 1997 |
Goetghebeur E, Molenberghs G. P52 Analyzing compliance in clinical trials: A sensitive point Controlled Clinical Trials. 18: S142. DOI: 10.1016/S0197-2456(97)91147-8 |
0.34 |
|
| 1997 |
Loeys T, Goetghebeur E. 80 Structural failure time models for causal inference in clinical trials Controlled Clinical Trials. 18: S91. DOI: 10.1016/S0197-2456(97)91065-5 |
0.614 |
|
| 1996 |
Andersen J, Goetghebeur E, Ryan L. Missing Cause Of Death Information In The Analysis Of Survival Data Statistics in Medicine. 15: 2191-2201. PMID 8910963 DOI: 10.1002/(Sici)1097-0258(19961030)15:20<2191::Aid-Sim358>3.0.Co;2-D |
0.355 |
|
| 1996 |
Goetghebeur E, Molenberghs G. Causal inference in a placebo-controlled clinical trial with binary outcome and ordered compliance Journal of the American Statistical Association. 91: 928-934. DOI: 10.1080/01621459.1996.10476962 |
0.424 |
|
| 1995 |
Goetghebeur E, Ryan L. Analysis of competing risks survival data when some failure types are missing Biometrika. 82: 821-833. DOI: 10.1093/Biomet/82.4.821 |
0.365 |
|
| 1991 |
Goetghebeur E, Shipley M, Pocock S, Farchi G. Estimating effects of change in individual risk factors in a multifactorial intervention trial with group randomization Controlled Clinical Trials. 12: 639. DOI: 10.1016/0197-2456(91)90126-7 |
0.365 |
|
| Show low-probability matches. |
